Citation Tools
PDFRegular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
498 ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 498 ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response